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Abstract
Recently, molecular fingerprints extracted from three-dimensional (3D) structures using advanced mathemat-
ics, such as algebraic topology, differential geometry, and graph theory have been paired with efficient machine
learning, especially deep learning algorithms to outperform other methods in drug discovery applications and
competitions. This raises the question of whether classical 2D fingerprints are still valuable in computer-aided
drug discovery. This work considers 23 datasets associated with four typical problems, namely protein-ligand
binding, toxicity, solubility and partition coefficient to assess the performance of eight 2D fingerprints. Advanced
machine learning algorithms including random forest, gradient boosted decision tree, single-task deep neural
network and multitask deep neural network are employed to construct efficient 2D-fingerprint based models.
Additionally, appropriate consensus models are built to further enhance the performance of 2D-fingerprint-
based methods. It is demonstrated that 2D-fingerprint-based models perform as well as the state-of-the-art 3D
structure-based models for the predictions of toxicity, solubility, partition coefficient and protein-ligand binding
affinity based on only ligand information. However, 3D structure-based models outperform 2D fingerprint-based
methods in complex-based protein-ligand binding affinity predictions.
I Introduction
Drug discovery is a multi-parameter optimization process, which involves a long list of chemical, biological, and
physiological properties.1 For a drug candidate, numerous drug-related properties must be assessed, including
binding affinity, toxicity, octanol-water partition coefficient (Log P), aqueous solubility (Log S), etc. Binding affinity
assesses the strength of a drug’s binding to its target,2,3 while, toxicity is a measure of the degree to which a
chemical compound can damage an organism adversely.4 In addition, a partition coefficient is defined as the
ratio of concentrations of a solute in a mixture of two immiscible solvents at equilibrium and, in the case of log
P, represents the drug-relatedness of a compound as well as its hydrophobic effect on human bodies.5 Another
relevant drug attribute is aqueous solubility which plays a vital role in distribution, absorption, and biological
activity, among other processes because 65-90 % of body mass is water.6,7 Their importance to drug design and
discovery has been emphasized by many recent surveys.8,9 Indeed, unsatisfactory toxicity or pharmacokinetic
properties are responsible for approximately half of drug candidate failures to reach the market.10
Traditional experiments for measuring drug properties are conducted either in vivo or in vitro. Such experi-
ments are quite time consuming and expensive. Additionally, testing with animals can raise important ethical
concerns. Therefore, various computer-aided or in silico methods become more attractive since they can pro-
duce quick results without sacrificing much accuracy in many situations. Among them, one of the most popular
approaches is the quantitative structure-activity/property relationship (QSAR/QSPR) analysis. It assumes that
similar molecules have similar bioactivities or physicochemical properties.11 Based on this assumption, activities
and properties of new molecules can be predicted by studying the correlation between chemical or structural
features of molecules and their activities or properties, reducing the need for time-consuming experiments.
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Molecular fingerprints are one way of encoding the structural features of a molecule. They play a fundamental
role in QSAR/QSPR analysis, virtual screening, similarity-based compound search, target molecule ranking,
drug ADMET prediction, and other drug discovery processes. Molecular fingerprints are property profiles of
a molecule, usually in the form of vectors with each vector element indicating the existence, the degree or
the frequency of one particular structure feature.12–14 Various fingerprints have been developed for molecular
feature encoding in the past few decades.15–17 Most fingerprints are 2D fingerprints which can be extracted from
molecular connection tables without 3D structure information. However, high dimensional fingerprints have also
been developed to utilize 3D molecular structure and other information.18
There are four main categories of 2D fingerprints, namely substructure key-based fingerprints, topological or
path-based fingerprints, circular fingerprints, and pharmacophore fingerprints. Substructure key-based finger-
prints are bit strings representing the presence of certain substructures or fragments from a given list of structural
keys in the compound. Molecular access system (MACCS)19 is one of the most popular substructure key-
based fingerprint methods. Topological or path-based fingerprints are based on analyzing all the fragments of a
molecule following a (usually linear) path up to a certain number of bonds, and then hashing every one of these
paths to create one fingerprint. The most prominent ones in this category are FP2,20 Daylight21 and electro-
topological state (Estate)22 fingerprints. Circular fingerprints are also hashed topological fingerprints but rather
than looking for paths in a molecule, they record the environment of each atom up to a pre-determined radius.
A well-known example for this class is extended-connectivity fingerprint (ECFP).15 Pharmacophore fingerprints
include the relevant features and interactions needed for a molecule to be active against a given target, includ-
ing 2D-pharmacophore,23 3D-pharmacophore23 and extended reduced graph (ERG)24 fingerprints as examples.
Since 2D fingerprints only rely on the 2D structures, their generation is easy, fast and convenient.
In addition to the four categories mentioned above, recent improvements in deep learning have enabled the
creation of neural fingerprints25,26âA˘Tˇ where the mapping between fingerprints and 2D structures is learned si-
multaneously with the parameters of the regression/classification model that maps fingerprints to targets. These
âA˘ŸlearnedâA˘Z´ fingerprints can potentially improve predictive performance on QSAR/QSPR tasks, but they
must be relearned when trying to predict new properties across significantly different regions of chemical space.
Since the focus of this work is on comparing 2D and 3D descriptors across a number of disparate tasks and
chemically diverse datasets, we have chosen not to consider neural fingerprints.
Most commonly used 2D molecular fingerprints were derived over a decade ago and their validation was car-
ried out using classical regression or classification algorithms, such as linear regression, logistic regression,
logistic classification, naive Bayes, k-nearest neighbors, support vector machine, etc. On the other hand, new
3D structure-based fingerprints built from algebraic topology,27,28 differential geometry,29 geometric graph the-
ory,30,31 and algebraic graph theory32 have been developed in recent years. In particular, these new fingerprints
were mostly paired with advanced machine learning algorithms, such as random forest (RF),33 gradient boost-
ing decision tree (GBDT),34 single-task deep neural networks (ST-DNNs),35 multi-task deep neural networks
(MT-DNNs),36 convolutional neural network (CNN), recurrent neural network (RNN), etc. methodology, which
are now easily accessible to the scientific community via user-friendly deep learning frameworks in popular
programming languages.37,38 Often, these new methods have demonstrated higher accuracy or better perfor-
mance than earlier methods in the literature, which are typically based on 2D fingerprints and/or simple machine
learning algorithms for drug discovery related applications, such as protein-ligand binding,27 virtual screening,28
toxicity,4 solubility,5 partition coefficient,5 as well as protein folding stability change upon mutation.39 Addition-
ally, recent results from D3R Grand Challenges, a community-wide annual competition series in computer-aided
drug design, indicate that structure-based methods using sophisticated 3D structure-based fingerprints have an
advantage over ligand-based methods using 2D fingerprints in scoring and free energy predictions.32,40 These
developments raise an interesting question of whether 2D fingerprints are still valuable for drug design and
discovery. Therefore, there is pressing need to reassess 2D fingerprints with advanced machine learning algo-
rithms and compare their performance with the state-of-the-art 3D structure-based fingerprints for drug discovery
related applications.
The objective of the present work is to reassess the predictive power of eight popular 2D fingerprints for
four important drug-related problems, namely, toxicity, binding affinity, Log P, and Log S, involving a total of
23 datasets. These problems are selected for the availability of reference results generated by the state-of-the-
art 3D structure-based fingerprints in the literature. To optimize 2D fingerprints’ performance, advanced machine
learning algorithms, including RF, GBDT, ST-DNN, and MT-DNN, are employed in the present study. Additionally,
consensus models are constructed from appropriate combinations of 2D fingerprint-based predictions to further
2
enhance their performance. The predictive power of each 2D fingerprint for certain functional groups is analyzed.
Extensive numerical studies over 23 datasets using eight 2D fingerprints and four different machine learning al-
gorithms indicate that the combination of appropriate machine learning algorithms and 2D fingerprint-based
models, particularly consensus models, can bring significant improvements over previous 2D QSPR approaches
especially on toxicity predictions.41 Moreover, 2D fingerprint-based models perform as well as the state-of-the-
art 3D structure-based fingerprints in the predictions of toxicity, solubility, partition coefficient and ligand-based
protein-ligand binding affinity. Finally, topology-based fingerprints extracted from 3D protein-ligand complexes
have a significant advantage over 2D fingerprints in complex-based protein-ligand binding affinity predictions.
We believe that the present performance analysis and assessment will provide a useful guideline on how to
choose appropriate fingerprints and machine learning methods for drug discovery related applications.
II Methods
II.A 2D fingerprints
In the present work, we investigate eight popular 2D fingerprints, including FP2 fingerprint, MACCS fingerprint,
Daylight fingerprint, Estate1 fingerprint, Estate2 fingerprint, ECFP4 Fingerprint, 2D-pharmacophore (Pharm2D),
and extended reduced graph fingerprint (ERG). They are chosen to represent four main 2D molecular fingerprint
categories, namely key-based fingerprints, topological or path-based fingerprints, circular fingerprints, pharma-
cophore fingerprints. These features are some of the most popular and commonly used ones. Table 1 sum-
marizes the information related to these fingerprints. All 2D fingerprints were generated by Openbabel (version
2.4.1)20 and RDKit (version 2018.09.3).23
II.B Ensemble methods
Two popular ensemble methods were used in our work. The first method is random forest (RF), which con-
structs a multitude of decision trees during a training process. RF can be used to predict a classification label
(classification model) or a mean prediction (regression model) of the individual trees. It is very robust against
overfitting and easy to use. The second method is gradient boosting decision tree (GBDT). In this approach, indi-
vidual decision trees are combined in a stage-wise fashion to achieve the capability of learning complex features.
It uses both gradient and boosting strategies to reduce model errors. Compared to deep neural network (DNN)
approaches, these two ensemble methods are robust, relatively insensitive to hyper parameters, and easy to
implement. Moreover, they are much faster to train than DNN is. In fact, for small datasets, RF and GBDT can
perform even better than DNN or other deep learning algorithms. Therefore, these methods have been applied
to a variety of QSAR prediction problems, such as toxicity, solvation, and binding affinity predictions.4,27,41,43,44
II.C Single-task deep neural network (ST-DNN)
A DNN mimics the learning process of a biological brain by constructing a wide and deep architecture of
numerous connected neuron units. A typical deep neural network often includes multiple hidden layers. In each
layer, there are hundreds or even thousands of neurons. During learning stages, weights on each layer are
updated by backpropagation. With a complex and deep network, DNN is capable of constructing hierarchical
features and model complex nonlinear relationships.
ST-DNN is a regular deep learning algorithm. It only takes care of one single prediction task. Therefore, it only
learns from one specific training dataset. A typical four-layer ST-DNN is showed in figure 1, where Ni (i = 1, ...,
4), represents the number of neurons in the ith hidden layer.
II.D Multitask deep neural network (MT-DNN)
The multitask (MT) learning technique has achieved much success in qualitative Merck and Tox21 prediction
challenges.45–48 In the MT framework, multiple tasks share the same hidden layers. However, the output layer
is attached to different tasks. This framework enables the neural network to learn all the data simultaneously for
different tasks. Thus, the commonalities and differences among various datasets can be exploited. It has been
showed that MT learning typically can improve the prediction accuracy of relatively small datasets if it combines
with relatively larger datasets in its training.
Figure 2 is an illustration of a typical four-layer MT-DNN for training four different tasks simultaneously. Suppose
there are totally T tasks and the training data for the tth task are (Xti , y
t
i)
Nt
i=1, where t = 1, . . . , T , i = 1, . . . , Nt,
Nt is the number of samples in the tth task, and Xti is the feature vector for the ith sample in the tth task, y
t
i is
the label value of the ith sample in the tth task, respectively. The purpose of MT learning is to simultaneously
minimize the loss function:
argmin
∑T
t=1
∑Nt
i=1 L(y
t
i , f
t(Xti , θ
t))
where f t is the prediction for the ith sample in the tth task by our MT-DNN, which is a function of the feature
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Fingerprint Description Number of features Package
FP2
A path-based fingerprint which indexes
small molecule fragments based on lin-
ear segments of up to 7 atoms20
256 Openbabel20
Daylight
A path-based fingerprint consisting
2048 bits and encoding all connectiv-
ity pathways in a given length through
a molecule21
2048
RDKit23
MACCS
A substructure keys-based fingerprint
with 166 structural keys based on
SMARTS patterns19
166
Estate1
A topological fingerprint based on
electro-topological State Indices,
which encodes the intrinsic electronic
state of the atom as perturbed by the
electronic influence of all other atoms
in the molecule within the context
of the topological character of the
molecule. Estate 1 represents the
number of times each atom type is
hit22
79
Estate2
Similar to estate 1, however it contains
the sum of the EState indices for atoms
of each type22
79
ECFP4
The de facto standard circular finger-
print based on the Morgan algorithm,42
which uses an iterative process to as-
sign numeric identifiers to each atom15
2048
Pharm2D
Each bit corresponds to a particular
combination of features and interac-
tions needed for a molecule to be ac-
tive against a given target23
990
ERG
A Pharmacophore fingerprint, which is
an extended reduced graph approach
using pharmacophore-type node de-
scriptions to encode the relevant
molecular properties24
315
Table 1: A introduction of eight fingerprints used in the present study.
vector Xti , L is the loss function, and θ
t is the collection of machine learning hyperparameters. A popular cost
function for regression is the mean squared error, which can be defined as:
L(yti , f
t(Xti , θ
t)) = 1Nt
∑Nt
i=1 (y
t
i − f t(Xti , θt))2.
In this study, MT learning technology is applied to the toxicity prediction. The ultimate goal of this MT learning
is to potentially improve the overall performance of multiple toxicity prediction models, especially for the smallest
dataset that performs relatively poorly in the ST-DNN. More concretely, it is reasonable to assume that different
toxicity indexes share a common pattern so that these different tasks can be trained simultaneously when their
feature vectors are constructed in the same manner. For our toxicity prediction, four different tasks (LD50, IGC50,
LC50, LC50-DM data sets) are trained together. This leads to four output neurons in the output layer (See O1 to
O4 in Figure 2), with each neuron being specific to one of four tasks.
II.E Hyperparameters
Ensemble hyperparameters. Both RF and GBDT were implemented by the scikit-learn package (version
0.20.1).49 In this work, there are a total of 23 datasets with their training data size varying from 94 to 8199.
RF has been showed to be consistent and robust with various datasets. However, if its parameters are carefully
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Figure 1: An illustration of a typical ST-DNN. Only one task (data set) is trained in this network. Four hidden
layers are included, ki (i = 1, 2, 3, 4) represents the number of neurons in the ith hidden layer and Ni,j is the jth
neuron in the ith hidden layer. Here, O1 is the single output for the task.
Figure 2: An illustration of a typical MT-DNN training four tasks (datasets) simultaneously. Four hidden layers
are included in this network, ki (i = 1, 2, 3, 4) represents the number of neurons in the ith hidden layer and Ni,j
is the jth neuron in the ith hidden layer. Here O1 to O4 represent four predictor outputs for four tasks.
tuned based on the size of a given training set, GBDT can attain better performance than RF does in most
cases. For all experiments in this work, the most essential parameters of GBDT are chosen as learning rate =
0.01, min_samples_split = 3, max_features=sqrt. Detail values of other parameters are given in Table 2.
Network hyperparameters. Since the numbers of features differ much in different 2D fingerprints, different
network architectures have to be adopted. For example, Estate 1 fingerprint has only 79 bits. Therefore a 4-
layer network with the number of neurons in various hidden layers are chosen as 500, 1000, 1500, and 500.
However, the Daylight fingerprint has as many as 2048 features, and thus a much larger network is needed. The
network for this fingerprint still has 4 layers but there are 3000, 2000, 1000, and 500 neurons in the first, second,
third and fourth hidden layer, respectively. Other network parameters are as followed: the optimizer is stochastic
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Training-set size RF parameters GBDT parameters
<800
n_estimators=1000, criterion=‘mse’,
max_depth=None,
min_samples_split=2,
min_samples_leaf=1,
min_weight_fraction_leaf=0.0
n_estimators=2000, max_depth=9,
min_samples_split=3, learn-
ing_rate=0.01, subsample=0.1,
max_features=’sqrt’
800 to 5000
n_estimators=10000,
max_depth=7,min_samples_split=3,
learning_rate=0.01, subsample=0.3,
max_features=’sqrt’
5000 to 10000
n_estimators=20000,
max_depth=7,min_samples_split=3,
learning_rate=0.01, subsample=0.3,
max_features=’sqrt’
Table 2: RF and GBDT parameters for different training-set sizes.
gradient descent (SGD) with momentum of 0.5. 2000 epochs were run for all the networks. Mini-batch size is
set to 4. The learning rate is set to 0.01 in the first 1000 epochs and 0.001 for the rest epochs. Our tests indicate
that adding a dropout or using L2 decay does not necessarily improve the accuracy, and thus, we omit these two
techniques. All the network hyperparameters are summarized in Table 3. These hyperparameters are applied to
both ST-DNN and MT-DNN. All the DNN training is performed by Pytorch (version 1.0).50
Fingerprint Number
of
features
Number of
hidden
layers
Number of
neurons in each
hidden layer
Optimizer Mini-
batch
Learning
rate
Estate1 79
4 500,1000,1500,500
SGD with a
momentum
of 0.5
4
First 1000:
0.01; Then:
0.001
Estate2 79
Daylight 2048 3000,2000,1000,500
Table 3: The network hyperparameters for both ST-DNN and MT-DNN.
III Results
III.A Toxicity prediction
Four toxicity datasets were studied in our work, namely oral rat LD50 (LD50), 40 h Tetrahymena pyriformis
IGC50 (IGC50), 96 h fathead minnow LC50 (LC50), and 48 h Daphnia magna LC50 (LC50-DM). Among them,
LD50 measures the amount of chemicals that can kill half of rats when orally ingested. IGC50 records the 50%
growth inhibitory concentration of Tetrahymena pyriformis organism after 40 h. LC50 reports at the concentration
of test chemicals in water in milligrams per liter that cause 50% of fathead minnows to die after 96 h. The last
one is LC50-DM, which represents the concentration of test chemicals in water in milligrams per liter that cause
50% Daphnia maga to die after 48 h. The unit of toxicity reported in these four datasets is -log10 mol/L. All of
them are accessible from the recent publications41,51,52 and the public database (https://www.epa.gov/chemical-
research/toxicity-estimation-software-tool-test). The sizes of these four datasets vary from 353 to 7413 (See
Table 4), which raises a challenge for a predictive model to achieve a consistent accuracy and robustness.
Data set Total size Train set size Test set size Max value Min value
LD50 7413 5931 1482 7.201 0.291
IGC50 1792 1434 358 6.36 0.334
LC50 823 659 164 9.261 0.037
LC50-DM 353 283 70 10.064 0.117
Table 4: The quantitative summary of four toxicity datasets. The original datasets and prediction results are
available at https://www.epa.gov/chemical-research/toxicity-estimation-software-tool-test.
III.A.1 The performance of ensemble methods
Because it is easy to implement and fast to train, two ensemble methods, RF and GBDT, were first tested.
Since four datasets have very different sizes, different numbers of estimators in RF and GBDT models should be
used. Specifically, for two relatively small sets, LC50 and LC50-DM, the numbers of estimators are set to 2000.
For IGC50, 10000 estimators are used. For the largest set LD50, we have used 20000 estimators.
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The accuracy is in term of the square of Pearson correlation coefficient (R2). Overall, GBDT’s performance is
always better than that of RF, which agrees with early publication.4 Among all the eight fingerprints we tested,
Estate2, Estate1, Daylight, FP2, ECFP and MACCS usually work well on these four sets. Thus the consensus of
these six fingerprints was also considered (“Top 6-cons” in Figure 3). The consensus model typically gives rise
to a further improvement over all single fingerprints in most cases.
Figure 3: The R2 on LD50, IGC50, LC50, LC50-DM test sets yielded by eight fingerprints and the consensuses of
the top 6 features. Two ensemble methods were adopted (GBDT: blue, RF: red). The values shown in the figure
are the R2 of GBDT.
(a)LD50 test set. LD50 dataset is the largest set having as many as 7413 compounds. However, a higher
experimental uncertainty of the values in this set makes this set relatively difficult to predict (See "Max value"
and "Min value" in Table 4). In our GBDT model, the best single fingerprint (MACCS) yields an R2 of 0.643, while
the consensus of the top 6 fingerprints increases R2 to 0.679.
(b) IGC50 test set. IGC50 set is the second largest set (1792 compounds) among the four sets we investigated.
As indicated in Table 4, the diversity of molecules of in this set is the lowest among the four sets, which means
the prediction should be some easier. Our results show that Estate2 is the best single fingerprint with an R2 of
0.742, and the consensus of the top 6 fingerprints leads to an R2 of 0.785.
(c) LC50 test set. LC50 set is a relative smaller set (823 compounds). By employing GBDT model, estate2
fingerprint achieves the top performance, which yields an R2 of 0.662. The consensus of the top 6 fingerprint
improves the R2 to 0.715.
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(d) LC50-DM test set. Among the four sets, LC50-DM test set is the smallest one with only 283 training molecules
and 70 test molecules, which is troublesome to build a robust model. Therefore, our model just generates
moderate results. Specifically, the best single fingerprint Estate1 only has an R2 of 0.520. The consensus model
even ruins the R2 a little bit with an R2 as low as 0.486. Similar difficulty is also faced by other recent work, such
as the R2 of the 3D-topology based GBDT model only reaches 0.505.4 Thus, there is a need for multitask deep
learning when dealing with such a small dataset.
III.A.2 The performance of single-task and multitask deep learning
On average, Estate2, Estate1, and Daylight are the top three fingerprints when using GBDT models in all the
four sets. Thus, these three fingerprints were picked up to perform higher-level ST-DNN and MT-DNN.
Since the lengths of the three fingerprints differ much, different DNN architectures are needed. Four hidden
layers with 500, 1000, 1500, and 500 neurons are used for Estate1 and Estate2, whose fingerprints have 79
features. Four hidden layers with 3000, 2000, 1000, and 500 neurons are used for Daylight, whose fingerprint
has 2048 bits.
The pattern of ST-DNN results is similar to that of GBDT results. On four data sets, a ST-DNN consensus model
yields an average R2 of 0.658 (0.632, 0.791, 0.687, and 0.523 respectively). As a comparison, the average R2
by a GBDT consensus model is 0.666 (0.679, 0.785, 0.715, and 0.486 respectively). However, the performance
can be largely enhanced by the multitask strategy because the two relatively smaller sets LC50 and LC50-DM
can benefit much from two larger sets LD50 and IGC50. As shown in Table 5, while the MT-DNN model seldom
changes the performance on LD50 and IGC50, it gives rise to a dramatic improvement on LC50 and LC50-DM,
especially on LC50-DM. The consensus lifts the R2 result from 0.523 to 0.725.
Method R2 of LD50 R2 of IGC50 R2 of LC50 R2 of LC50-DM
Estate2 ST-DNN 0.484 0.715 0.569 0.433
Estate2 MT-DNN 0.489 0.696 0.660 0.623
Estate1 ST-DNN 0.569 0.733 0.650 0.601
Estate1 MT-DNN 0.566 0.735 0.694 0.684
Daylight ST-DNN 0.619 0.701 0.570 0.346
Daylight MT-DNN 0.617 0.717 0.724 0.694
Consensus ST-DNN 0.632 0.791 0.687 0.523
Consensus MT-DNN 0.639 0.794 0.765 0.725
Table 5: The R2 of ST-DNN and MT-DNN based on the top 3 fingerprints in GBDT (Estate2, Estate1, Daylight)
and their consensuses.
III.A.3 Systematic comparison with other toxicity predictions
A systematic comparison with other methods was provided in Table 6. The same datasets are also used
to develop the Toxicity Estimation Software Tool (T.E.S.T). So many related results can be found in its user’s
guide,41 including hierarchical, single model, FDA, group contribution, nearest neighbor, and T.E.S.T consensus.
Since T.E.S.T is also based on 2D descriptors, the comparison between the results from the present models and
T.E.S.T can largely reflect the predictive power of the present models. As shown in Table 6, on the LD50, IGC50,
LC50 sets, the present MT-DNN consensus always leads to a higher R2 than T.E.S.T consensus. Especially,
on the IGC50 and LC50 sets, the present MT-DNN consensus models largely beat T.E.S.T (0.794 vs 0.764 and
0.765 vs 0.728), and the present GBDT results quite outperform T.E.S.T (0.679 vs 0.626) on the LD50 set. Even
on the LC50-DM set, because the training set is so small (283), ensemble methods (RF and GBDT) and DNN
methods are not suitable for it: R2 of ST-DNN and GBDT are, respectively, 0.486 and 0.523. However, the R2 of
MT-DNN is as high as 0.725 for LC50-DM dataset, which is quite comparable to the T.E.S.T result with an R2 of
0.739.
2D MT-DNN consensus has an average R2 of 0.731 for these four datasets, while the average of T.E.S.T model
is 0.714, and the recent 3D structure-based topological MT-DNN consensus result is also 0.731.4 These results
confirm that 2D fingerprints integrated with MT-DNN model surpass the previous 2D models and are as good as
the recent 3D structure-based topological model.4
III.B Aqueous solubility (Log S)
For Log S, following the previous literature,5,53 we test Klopman’s test set54 with the original train set. The unit
of Log P in these sets is log unit. Since the size of the training set is 1290, 10000 estimators were used in the
GBDT model.
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LD50
Method R2 RMSE Coverage
The present 2D MT-DNN consensus 0.639 0.549 1.000
The present 2D GBDT consensus 0.679 0.580 1.000
Hierarchical41 0.578 0.650 0.876
FDA41 0.557 0.657 0.984
Nearest neighbor41 0.557 0.656 0.993
T.E.S.T consensus41 0.626 0.594 0.984
3D MT-DNN consensus4 0.653 0.568 0.997
IGC50
Method R2 RMSE Coverage
The present 2D MT-DNN consensus 0.794 0.457 1.000
The present 2D GBDT consensus 0.785 0.457 1.000
Hierarchical41 0.719 0.539 0.933
FDA41 0.747 0.489 0.978
Group contribution41 0.682 0.575 0.955
Nearest neighbor41 0.600 0.638 0.986
T.E.S.T consensus41 0.764 0.475 0.983
3D MT-DNN consensus4 0.802 0.438 1.000
LC50
Method R2 RMSE Coverage
The present 2D MT-DNN consensus 0.765 0.718 1.000
The present 2D GBDT consensus 0.715 0.783 1.000
Hierarchical41 0.710 0.801 0.951
Single model41 0.704 0.803 0.945
FDA41 0.626 0.915 0.945
Group contribution41 0.686 0.810 0.872
Nearest neighbor41 0.667 0.876 0.939
T.E.S.T consensus41 0.728 0.768 0.951
3D MT-DNN consensus4 0.789 0.677 1.000
LC50-DM
Method R2 RMSE Coverage
The present 2D MT-DNN consensus 0.725 0.935 1.000
The present 2D GBDT consensus 0.486 1.239 1.000
Hierarchical41 0.695 0.979 0.886
Single model41 0.697 0.993 0.871
FDA41 0.565 1.190 0.900
Group contribution41 0.671 0.803 0.657
Nearest neighbor41 0.733 0.975 0.871
T.E.S.T consensus41 0.739 0.911 0.900
3D MT-DNN consensus4 0.678 0.978 1.000
Table 6: Comparison to other toxicity prediction methods. The prediction results for Hierarchical, Single
model, FDA, Group contribution, Nearest neighbor, and T.E.S.T consensus are available in reference 44 and
at https://www.epa.gov/chemical-research/toxicity-estimation-software-tool-test.
Training set Klopman’s test set
1290 21
Table 7: The sizes of Log S training set and Klopman’s test set.
In the Log S test, the top 6 fingerprints are MACCS, FP2, Daylight, Estate1, Estate2, and ECFP, which perform
much better than the other two fingerprints, Pharm2D and ERG. The consensuses of the top 6 fingerprints
results in R and RMSE of 0.944 and 0.684, respectively. The consensus of top 3 is even better, which improves
R and RMSE to 0.955 and 0.648 (See Table 8). A systematic comparisons to other methods are included in
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Fingerprint R RMSE
Cons-top 3 0.955 0.648
Cons-top 6 0.944 0.684
MACCS 0.958 0.664
Estate1 0.932 0.791
Daylight 0.923 0.780
FP2 0.908 0.853
ECFP 0.904 0.875
Estate2 0.897 0.907
Pharm2D 0.832 1.114
ERG 0.811 1.202
Table 8: The R and RMSE of predicting Log S by eight fingerprints and the consensuses of the top 3 and top 6
on Klopman’s test set.
Method R RMSE
Cons-top 3 0.955 0.648
Cons-top 6 0.944 0.684
MT-ESTD+-1 (3D)5 0.94 0.69
Drug-LOGS (2D)53 0.94 0.64
Klopman MLR (2D)54 0.92 0.86
Table 9: Comparison of prediction results on the Log S data set.
Table 9. It indicates the present method outperforms all other state-of-the-art 3D and 2D methods.
III.C Partition coefficient (Log P)
Three Log P data sets were tested using the GBDT model. The training set has 8199 molecules, which was
originally compiled by Cheng et al.55 There are three test sets, namely FDA,55 Star,56 and Non-star56 respec-
tively, which are given in Table 10. The Log P in these sets is by the unit of log10 mol/L. Due to the size of the
training set, 20000 estimators are used in the GBDT model.
Test setTraining set FDA Star Non-star
8199 406 223 43
Table 10: The sizes of Log P training set and test sets.
In order to easily compare to the earlier literatures, accuracy on these three test sets are reported by R2 or
acceptable rate. The acceptable rate here is defined as the percentage of molecules within error range < 0.5.57
Of all the three sets, the 2D fingerprints of Estate2, Estate1, MACCS, and ECFP are always the top 4. The
consensuses of the top 4 fingerprints produce R2 up to 0.901 on the FDA set and attain an acceptable rate on
Star set at 71.3%. On the Non-star set, the top 4 consensus is somehow worse than the best single fingerprint
Estate1 but it is still in the second place with an acceptable rate of 46.5% (See Figure 4).
A detailed comparison with other Log P prediction methods was shown in Table 11. On the FDA data set,
GBDT-ESTD+-2-AD5 and MT-ESTD-15 are based on 3D descriptors. GBDT-ESTD+-2-AD model includes some
molecules from the NIH-dataset in its training set. Therefore, its performance is slightly better than the present
one. The 2D method ALOGPS55 also performs slightly better (0.908 vs 0.901) than the present one. However,
a previous study53 has pointed out that for the PHYSPROP database,58 the training set of ALOGPS actually
contains all of the compounds in the FDA set. It is unclear how well it will perform if the overlapping compounds
are removed from the training set. Unlike ALOGPS, XLOGP3’s training data is completely independent of the
test set.55 In this case, the present prediction is more accurate than that of XLOGP3 (0.901 vs 0.872).
The present results on the Star and Non-star sets are also systematically compared with other stat-of-the-
art models as shown in Table 12. For the Star set, we achieve 71% of total number of molecules having the
predicted error less than 0.5 (acceptable rate 71%). This result is quite satisfactory and is comparable to the
3D structure-based model developed by Wu et al.5 with an acceptable rate of 72% on the same training set
(“MT-ESTD-1" in Table 12). There are many commercial software packages developed to predict Log P such
as AB/Log P,57 S/Log P,57 ACD/log P,57 etc. However, we cannot validate whether the training sets used in
these software packages overlap with the Star set. It is more meaningful when comparing the present model to
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Figure 4: The performance of eight fingerprints and the consensuses of the top 4 on the FDA, Star and Non-star
data sets of Log P. To be consistent with previous results, on the FDA set, R2 is given, while on star and non-star
datasets, acceptable rate is given.
Method R2 RMSE
GBDT-ESTD+-2-AD (2D+3D)5 0.935 0.51
MT-ESTD-1 (3D)5 0.920 0.57
ALOGPS (2D but the training set contains test set)55 0.908 0.60
Our Cons-top 4 (2D) 0.901 0.63
XLOGP3 (2D)55 0.872 0.72
XLOGP3-AA (2D)55 0.847 0.80
CLOGP (2D)55 0.838 0.88
TOPKAT (2D)55 0.815 0.88
ALOGP98 (2D)55 0.80 0.90
KowWIN (2D)55 0.771 1.10
HINT (2D)55 0.491 1.93
Table 11: Comparison of Log P predictions on the FDA set.
XLogP3 software57 since its training dataset does not contain any molecules in the test set. Again, the present
model outperforms XLogP3 package on the Star set with the acceptable rates being 71% and 60%, respectively.
In the Non-star set, all of the published methods perform as accurate as those in the FDA and Star data set,
since the structures in the Non-star set are relatively new and complex. Thus, our model also only achieves an
acceptable rate of 47%. However, it is still tied for the third place among all predictors. This result is even better
than some 3D structure-based models, though RMSE is relatively high due to a few large outliers.
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Star set (N=223) Non-star set (N=43)
% of Molecules
within error range
% of Molecules
within error range
Method <0.5 <1 RMSE <0.5 <1 RMSE
AB/LogP57 84 12 0.41 42 23 1.00
MT-ESTD+-1-AD5 77 16 0.49 49 19 0.98
S+logP57 76 22 0.45 40 35 0.87
ACD/logP57 75 17 0.50 44 32 1.00
CLOGP57 74 20 0.52 47 28 0.91
MT-ESTD-15 72 18 0.55 33 28 1.01
ALOGPS57 71 23 0.53 42 30 0.82
Our cons-top 4 71 18 0.625 47 16 1.233
MiLogP57 69 22 0.57 49 30 0.86
KowWIN57 68 21 0.64 40 30 1.05
TLOGP57 67 16 0.74 30 37 1.12
CSLogP57 66 22 0.65 58 19 0.93
SLIPPER-200257 62 22 0.80 35 23 1.23
XLOGP357 60 30 0.62 47 23 0.89
XLOGP257 57 22 0.87 35 23 1.16
QLOGP57 48 26 0.96 21 26 1.42
VEGA57 47 27 1.04 28 30 1.24
SPARC57 45 22 1.36 28 21 1.70
LSER57 44 26 1.07 35 16 1.26
CLIP57 41 25 1.05 33 9 1.54
MLOGP(Sim+)57 38 30 1.26 26 28 1.56
HINTLOGP57 34 22 1.80 30 5 2.72
NC+NHET57 29 26 1.35 19 16 1.71
Table 12: Comparison of Log P predictions of the Star and Nonstar sets.
III.D Protein-ligand binding affinity prediction
III.D.1 The S1322 dataset
To assess the predictive power of 2D-fingerprint based models, two protein-ligand binding affinity datasets
were investigated. The first one is denoted as the S1322 set. It is a high quality data set with 1322 protein-
ligand complexes involving 7 protein clusters (labeled as CL1, CL2, · · · , CL7). It is a subset of the refined set
of PDBbind v2015.59 The other dataset is PDBbind v2016,60 in which the refined set excluding the core set in
PDBbind v2016 is used as a training data. The core set is a test set. These two sets are summarized in Table 13.
S1322 set PDBBind v2016 refined set
CL1 CL2 CL3 CL4 CL5 CL6 CL7 refined set training set core set (test set)
333 264 219 156 134 122 94 4057 3767 290
Table 13: The quantitative summary of the S1322 and PDBbind v2016 data sets.
The ligand-based model is used in the present work. For the S1322 set, a 5-fold cross validation was conducted
with the GBDT method. To be consistent with the results in the previous literature, accuracy is in term of Pearson
correlation coefficient (R). Because the results from Daylight and Pharm2D fingerprints are relatively poor, their
results are omitted here. The performance of the other six fingerprints (ECFP, FP2, Estate2, MACCS, Estate1,
ERG) and their consensus are shown in Figure 5.
Figure 5 indicates that for all the seven clusters, the consensuses of the six fingerprints largely achieve better
performance than that of any single fingerprint. Specifically, the R values of consensus models are 0.717, 0.847,
0.708, 0.718, 0.831, 0.777, and 0.760 on each of 7 clusters, respectively and 0.765 on average. These results
are comparable to ones achieved by a ligand-based 3D topology and GBDT model.27
III.D.2 PDBbind v2016 refined set and core set
The present ligand-based model was also tested on PDBbind v2016. Rather than cross validation, this time the
core set is regarded as a test set. Quite consistent with core validation on the S1322 set, the consensus of the
six fingerprints leads to a large improvement than any single one, with an R of 0.747. These results indicate that
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Figure 5: Pearson correlation coefficient (R) on the seven clusters of the S1322 data set yielded by the six
fingerprints (ECFP, FP2, Estate 2, MACCS, Estate 1, ERG) and their consensuses.
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Figure 6: The R on the PDBbind v2016 binding affinity set yielded by the six fingerprints (ECFP, FP2, Estate 2,
MACCS, Estate 1, ERG) and their consensus.
the present model has a stable and reliable performance on different protein-ligand binding affinity data sets.
Method R RMSE (kcal/mol)
TopBP (Complex)28 0.861 1.65
PLEC FP (Complex)61 0.817 1.71
Our cons-top 6 (Ligand) 0.747 2.02
Table 14: Comparison of protein-ligand binding affinity predictions PDBbind v2016 core set.
For protein-ligand binding affinity prediction, the present 2D fingerprint-based model is not competitive, because
protein-ligand binding not only depends on the ligand, but also on the protein. Therefore, for a more accurate
prediction, the information of the protein, at least the information of the binding site should be included. State
differently, a complex based model is recommended. Recently, Wojcikowski et. al.61 reports 2D fingerprint-
based complex models. In their work, a recently developed 2D fingerprint model is used to encode protein-ligand
complex information. When combined with DNN, their method gives rise to an R of 0.817 on the PDBBind v2016
core set. A complicated 3D structure-based model using the topology of the protein-ligand complex developed
by our group28 has an R of 0.861 on the same set. Table 14 lists these results.
IV Discussion
IV.A General analysis
In the present work, the predictive power of eight popular 2D fingerprints as well as their consensuses on four
important drug-related properties (i.e., toxicity, Log S, Log P, binding affinity) was investigated. The present
study reveals that with a proper machine learning algorithm, the 2D fingerprint-based models including their
consensuses outperform other 2D QSPR approaches in the most cases, especially on the toxicity predictions.
Additionally, 2D fingerprint-based models are comparable to state-of-the-art 3D structure-based models in most
drug-related property predictions, except for protein-ligand binding affinity prediction. Considering 2D fingerprints
are very "cheap" molecular descriptors that are easy and fast to generate, our results are very impressive. It
means that 2D fingerprints with appropriate machine learning algorithms are still very valuable for practical
problems, such as the prediction of toxicity, the aqueous solubility (Log S), and the partition coefficient (Log P).
However, for protein-ligand binding affinity prediction, complex-based models using 3D topological fingerprints
have a major advantage over the present 2D fingerprints, i.e., about 15% more accurate.27
IV.B The performance analysis of 2D fingerprints
IV.B.1 Analysis of 2D fingerprints for PDBbind v2016 core set predictions
The performance of each 2D fingerprint can be systematically analyzed by comparing the difference between
prediction errors of every pair of fingerprints as follows.
(1) The relative absolute error for the f th fingerprint on the ith sample (molecule) in the test set is defined by
Errorf,i =
|prediction valuef,i − experimental valuei|
|experimental valuei|
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Figure 7: The ranked error differences between pairs of fingerprints for PDBbind v2016 core set of 290
molecules. Only the top 4 fingerprints (i.e., Estate2, FP2, Estate1, MACCS) are considered.
(2) For each molecule, the error difference between each pair of fingerprints is calculated.
(3) Then, the differences for all molecules are ranked from the largest to smallest. The result for PDBbind v2016
core set of 290 complexes is plot in Figure 7. We have shown all of 6 pairs for the top four 2D fingerprints.
(4) To further analyze the strength of each fingerprint on certain molecules, we collect those molecules on which
a fingerprint is able to outperform another fingerprint by 0.4 in the error difference.
(5) Among these molecules for each fingerprint, we identify the top 10 most frequently occurred functional
groups. The frequency of the occurrence of each functional group, along with the total of number of molecules,
are given in Table 15.
Ranking FP2 Estate1 Estate2 MACCS
15
1
carbonyl group: 24/41 carbonyl group: 25/42 carbonyl group: 23/41 bicyclic compounds:
17/36
2
unfused benzene ring:
21/41
unfused benzene ring:
18/42
unfused benzene ring:
22/41
pyridine: 17/36
3
bicyclic compounds:
19/41
aniline:14/42 carboxylate ion: 16/41 ether: 16/36
4
hydroxyl: 16/41 carboxylate ion: 14/42 bicyclic compounds:
15/41
carbonyl group 15/36
16
5
ether: 14/41 hydroxyl: 14/42 carbonyl group with N:
13/41
hydroxyl: 15/36
6
12/41 ether: 14/42 ether: 13/41 unfused benzene ring:
12/36
7
amide: 10/41 carbonyl with
Nitrogen: 13/42
hydroxyl: 11/41 amide: 10/36
8
azole: 8/41 amide: 11/42 amide: 11/41 carboxylate ion: 9/36
9 ......
multiple non-fused
benzene rings: 7/41
11/41 aniline: 10/41 azole: 7/36
17
10 ......
aniline: 7/41 phenol: 8/42
......
multiple non-fused
benzene rings 8/41
furan: 5/36
Table 15: The top 10 frequently occurred functional groups in PDBbind v2016 core set for each fingerprint. For
each fingerprint, the occurrence frequency and the total number of molecules are also given.
This analysis is quite significant as shown in Table 15. It indicates that different fingerprints have different per-
formance on certain functional groups: some fingerprints perform better on some functional groups, while other
fingerprints perform better on other functional groups. Therefore, one can select an appropriate fingerprint to
represent a certain class of functional groups based on Table 15. For the FP2, Estate1, and Estate2 fingerprints,
the top two functional groups are carbonyl groups and unfused benzene rings. However, the MACCS fingerprint
is some special. Its top two functional groups are bicyclic compounds and pyridine.
The third top functional groups differ much for four fingerprints: bicyclic compounds for FP2, aniline for Estate1,
carboxylate ion for Estate2, and ether for MACCS, which gives us more information to choose fingerprints. Such
as, if one has a molecule including aniline, then Estate1 should be selected. Noticeably, some functional groups
occur exclusively for one or two types of fingerprints. For example, F, Cl, Br, I is only on the lists of FP2 and
Estate1. While azole appears only on the list of FP2 and MACCS and multiple non-fused benzene rings are only
for FP2 and Estate 2. Moreover, phenol occurs only for Estate1 and furan occurs only for MACCS.
IV.B.2 Analysis of 2D fingerprints for the IGC50 toxicity data set prediction and also other data sets
Using the same 5-step procedure outlined above, we carry out a performance analysis for toxicity dataset IGC50,
which is shown in Figure 8 and Table 16. The molecules in the toxicity data set are typically small and simple,
leading to the functional groups in Table 16 also small. Moreover, since there are not too many functional groups
in these relatively simple molecules, only top 8 functional groups are presented in the table. Similar to the
performance on the binding affinity, for the top 4 fingerprints on the toxicity set, the carbonyl group is in the first
place. Unfused benzene rings also have a high occurrence frequency, resulting in the second or third ranking.
The difference between the performance of various fingerprints is mainly located on sulfide and aliphatic chains
with 8 or more members. FP2 fingerprint works well on sulfide, whereas, Daylight, Estate1 and Estate2 work
well on aliphatic chains with 8 or more members.
Ranking FP2 Daylight Estate1 Estate2
1
carbonyl group: 14/33 carbonyl group: 17/34 carbonyl group: 16/39 carbonyl group: 14/37
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2
unfused benzene ring:
21/41
hydroxyl: 9/34 hydroxyl: 15/39 hydroxyl: 14/37
3
amide: 9/33 unfused benzene ring:
9/34
unfused benzene ring:
9/39
unfused benzene ring:
10/37
4
hydroxyl: 9/33 amide: 7/34 ether: 7/39 ether: 8/37
5
ether: 8/33 ether: 7/34 6/39 8/37
6
5/33 6/34 amine: 6/39 amine: 6/37
7
sulfide: 3/33
aliphatic chains with 8
or more members:
5/34
aliphatic chains with 8
or more members:
6/39
aliphatic chains with 8
or more members:
5/37
8
aniline: 3/33 aniline: 4/34 aniline: 3/39 aniline: 5/37
Table 16: The top 10 frequently occurred functional groups in IGC50 toxicity set for each fingerprint. For each
fingerprint, the occurrence frequency and the total number of molecules are also given.
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Figure 8: The ranked error differences between pairs of fingerprints for IGC50 toxicity set of 358 molecules. Only
the top 4 fingerprints (i.e., Estate2, FP2, Estate1, Daylight) are considered.
The same performance analyses were also conducted for other toxicity and log P data sets, the results are
shown in Tables S1 to S4. These tables indicate, for the toxicity data sets of LD50, LC50, LC50-DM, the perfor-
mance of the Estate1 and Estate2 fingerprints are similar, they both work well on bicycle compounds; comparing
to it, the FP2 fingerprint works better on aliphatic chains with 8 or more members, the daylight fingerprint has a
better performance on amide. For log P data set, the ECFP and Estate2 fingerprints lead to a good performance
on aniline, the Estate 1 fingerprints works better on bicycle compounds; MACCS fingerprint works better on
unfused benzene ring.
IV.C The predictive power of the consensus of 2D fingerprints
The consensus of several different fingerprints typically further enhances the performance of a single fingerprint.
This enhancement can be quite significant. However, on the datasets of different drug-related properties, the
best fingerprint combinations for the consensus are not consistent. One possible explanation is that different
fingerprints are good at encoding certain functional groups, and datasets for different drug-related properties
have different functional group distributions. This is also the reason why a consensus can enhance performance.
The consensus can capture more functional groups and counter-balance the systematical bias from different
fingerprints.
On toxicity prediction, the best combination for consensus is obtained with Estate2, Estate1, Daylight, FP2,
ECFP, and MACCS. On the Log S prediction, the best combination is achieved with MACCS, Estate1, and
Daylight. While on the Log P prediction, the best consensus involves Estate2, Estate1, ECFP, and MACCS.
Finally, on the binding affinity prediction, the best consensus uses Estate2, Estate1, FP2, ECFP, MACCS, and
ERG. It is worth noting that, Estate related (Estate1, Estate2 or both) models are always included in the best
combinations. In fact, their single performances are relatively good. This finding is not surprising since Estate
fingerprints encode the intrinsic electronic state of the atom as perturbed by the electronic influence of all other
atoms. It is well-known that electronic state is important to drug-related properties.
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IV.D Multitask deep learning
Multitask deep learning was utilized on our toxicity prediction. It turns out that the smallest set LC50-DM with
only 283 training samples benefits dramatically from the multitask deep learning strategy. Its R2 value rises from
0.523 to 0.725. This is because, in the frame of multitask deep learning, different data sets (tasks) share similar
structure-function relationships. When a small dataset is trained with a large dataset through shared neural
networks, the statistics learned from the large datasets in the shared neurons can help predict the small dataset
property. As a result, the other three large toxicity sets can share their patterns learned from training with the
small toxicity set, enhancing its prediction. Therefore, multitask deep learning could be a useful strategy to train
relatively small datasets.
IV.E The limitation and advantage of 2D fingerprints
Typically, 2D fingerprints only encode small molecules, such as ligands, although high level 2D fingerprint mod-
els including both proteins and ligands have also been developed.61,62 Theoretically, 2D fingerprints are more
suitable for target-independent or target-unspecific problems involving small molecules, such as toxicity, solva-
tion free energy, aqueous solubility, partition coefficient, permeability, etc. The current investigation confirms this
point. For toxicity, aqueous solubility and partition coefficient, the present 2D-fingerprint based methods perform
quite similar to or even somewhat better than 3D structure-based methods in some cases.
For protein-ligand binding affinity predictions, both ligand-based approaches and complex-based are exam-
ined. For ligand-based approaches, 2D-fingerprint based methods can perform as well as 3D structure-based
models. However, 3D structure-based topological models28 outperform 2D-fingerprint based methods (i.e., R:
0.861 vs 0.747 for PDBbind v2016 core test). In fact, more sophisticated 2D fingerprint models that utilize the
protein-ligand complex information and DNN61,62 are still not as accurate as 3D topology-based models28(i.e.,
R: 0.817 vs 0.861 for PDBbind v2016 core test and 0.774 vs 0.808 for PDBbind v2013 core test). Essentially,
algebraic topology is designed to simplify the geometric complexity of biological macromolecules. Therefore, it
is able to extract vital information from protein-ligand complexes to predict their binding affinities.
2D fingerprints are much easier to generate than 3D structure-based fingerprints built form algebraic topology,
differential geometry or various graph theory. Therefore, 2D-fingerprint based models can be useful tools for
preliminary drug screening studies.
V Conclusion
Two-dimensional molecular fingerprints, or 2D fingerprints, refer to molecular structural patterns, such as ele-
mental composition, atomic connectivity, functional groups, 2D-pharmacophores etc. extracted from a molecule
without taking into account the 3D-structural representation of these properties. 2D fingerprints have been a main
workhorse for cheminformatics and bioformatics for decades. However, their validations in various datasets were
typically carried out long time ago with earlier machine learning algorithms. Recently, new 3D structure-based
molecular fingerprints built from algebraic topology,27,28 differential geometry,29 geometric graph theory,30,31 and
algebraic graph theory32 have found much success in drug discovery related applications,4,5,27,28 including D3R
Grand Challenges.32,40 It raises an interesting issue whether 2D fingerprints are still competitive in drug discov-
ery related applications.
This work reassesses 2D fingerprints for their performance in drug discovery related applications. We con-
sider a total of eight commonly used 2D fingerprints, namely FP2, Daylight, MACCS, Estate1, Estate2, ECFP,
Pharm2D, and ERG. Four types of drug discovery related applications with 23 datasets, including solubility (Log
S) and partition coefficient (Log P) that are independent of a target protein, toxicity that may depend on certain
unknown target proteins, and protein-ligand binding affinity that depend on known target proteins, are designed to
validate 2D fingerprints. Advanced machine learning algorithms, including random forest (RF), gradient boosting
decision trees (GBDT), single-task deep neural network (ST-DNN), and multitask deep neural network (MT-DNN)
are used to optimize the performance of the above 2D fingerprints in the aforementioned four types of datasets.
In particular, MT-DNN is designed to enhance the performance of 2D fingerprints on relatively small datasets
by a simultaneous training with relatively large datasets that share a similar pattern. Since each fingerprint may
have an explicit bias on certain functional groups or 2D patterns, we carry out various consensus to further
boost the performance of 2D fingerprints in all the datasets. Finally, the strengths of top four 2D fingerprints for
predicting protein-ligand binding affinity and quantitative toxicity are analyzed in detail.
Our general findings are as follows. 1) 2D fingerprint-based models are as good as 3D structure-based mod-
els for various toxicity, Log S and Log P datasets under the same training-test condition. 2) For ligand-based
protein-ligand binding affinity predictions, 2D fingerprint-based models perform equally well as 3D structure-
based models that are based only on ligand 3D structures. 3) 3D structure-based models that utilize 3D protein-
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ligand complex information outperform 2D fingerprints that based on either ligand information or protein-ligand
complex information. 4) Advanced machine learning algorithms, such as DNN and MT-DNN, are crucial for 2D
fingerprints to achieve optimal performance. 5) There is no 2D fingerprint that outperforms all other 2D finger-
prints in all applications. 6) Appropriate consensus of a few 2D models typically achieves better performance.
Therefore, if combined with advanced machine learning algorithms, the 2D fingerprints are still competitive in
most drug discovery related applications except for those that involve protein structures.
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